The purpose of this study is to evaluate the safety and tolerability of a drug called
semaglutide and to see whether it can reduce IHTG. IHTG will be measured by magnetic
resonance imaging (MRI; an MRI machine contains a powerful magnet that uses simple radio
waves to take pictures of organs). Semaglutide (brand name Ozempic®) is a drug that is used
to treat people who have diabetes; it also causes weight loss and may provide some protection
against cardiovascular disease and diabetes. In PLWH, the use of semaglutide to reduce weight
and the level of IHTG are experimental.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)